Viewing nowCombinationSitamet XR Extended-Release Tablet 100/1000 mg (Sitagliptin, Metformin)
Metformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.52mg
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.

MFDS item code 201505030 · Approved 2015.07.23 · Insurance code 643507360
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication helps improve blood sugar control when used in conjunction with dietary management and exercise prescriptions for patients with type 2 diabetes. Sitagliptin and metformin work together to effectively lower blood sugar levels. This can provide greater assistance in diabetes management. Regular use may lead to improved blood sugar control and contribute to health maintenance.
For antidiabetic therapy, determine the dose of this medicine based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine with a meal once daily, preferably in the evening, and increase the dose gradually. For this 100/1000 mg extended-release tablet, take 1 tablet once daily. Patients taking this 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control is not achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start with their current doses of sitagliptin and metformin. - Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this 50/1000 mg extended-release tablet once daily. 3. Patients who do not achieve adequate glycemic control with concomitant metformin and sulfonylurea, metformin and insulin, or metformin and thiazolidinedione therapy: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, discontinue this medicine immediately.
This medication contains two components, sitagliptin and metformin, and is primarily used for blood sugar control in patients with type 2 diabetes. Firstly, during the use of this medication, serious allergic reactions may rarely occur. If symptoms such as sudden skin rash, hives, difficulty breathing, or swelling of the face or neck appear, stop taking the medication immediately and consult with a healthcare professional. Additionally, cases of acute pancreatitis, which involves inflammation of the pancreas, have been reported. If symptoms like abdominal pain, nausea, vomiting, or fever occur, visit a hospital immediately. The metformin component can rarely cause a serious metabolic disorder known as lactic acidosis, which may manifest as muscle pain, difficulty breathing, fatigue, abdominal pain, and altered consciousness. If these symptoms appear, stop taking the medication immediately and inform a healthcare professional. Patients with decreased kidney function or severe liver dysfunction may be at risk when taking this medication, so it should not be administered. Especially for patients with moderate to severe kidney impairment, severe infections, dehydration, acute myocardial infarction, or sepsis, this medication should not be used, and it should be discontinued for a certain period before and after surgery. It is safer for pregnant or breastfeeding women not to use this medication. While taking this medication, symptoms of hypoglycemia may occur, especially with irregular eating, intense exercise, or when used together with other blood sugar-lowering medications. Furthermore, the risk of lactic acidosis increases when this medication is taken with alcohol, so it is advisable to avoid drinking. Long-term use of this medication may lower vitamin B12 levels, so it is necessary to monitor through regular blood tests. Finally, regular monitoring of kidney function and blood tests should be conducted during the use of this medication to ensure safe treatment.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a closed container to protect it from air and moisture. It is also advisable to keep the medication at room temperature between 1 to 30 degrees Celsius. Storing it this way will maintain its effectiveness and prevent deterioration.
Light blue, double convex, oval-shaped extended-release film-coated tablets
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.52mg
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.